A new piperidinol derivative targeting mycolic acid transport in Mycobacterium abscessus
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Summary: The natural resistance of Mycobacterium abscessus to most commonly available antibiotics seriously limits chemotherapeutic treatment options, which is particularly challenging for cystic fibrosis patients infected with this rapid‐growing mycobacterium. New drugs with novel molecular targets are urgently needed against this emerging pathogen. However, the discovery of such new chemotypes has not been appropriately performed. Here, we demonstrate the utility of a phenotypic screen for bactericidal compounds against M. abscessus using a library of compounds previously validated for activity against M. tuberculosis. We identified a new piperidinol‐based molecule, PIPD1, exhibiting potent activity against clinical M. abscessus strains in vitro and in infected macrophages. Treatment of infected zebrafish with PIPD1 correlated with increased embryo survival and decreased bacterial burden. Whole genome analysis of M. abscessus strains resistant to PIPD1 identified several mutations in MAB_4508, encoding a protein homologous to MmpL3. Biochemical analyses demonstrated that while de novo mycolic acid synthesis was unaffected, PIPD1 strongly inhibited the transport of trehalose monomycolate, thereby abrogating mycolylation of arabinogalactan. Mapping the mutations conferring resistance to PIPD1 on a MAB_4508 tridimensional homology model defined a potential PIPD1‐binding pocket. Our data emphasize a yet unexploited chemical structure class against M. abscessus infections with promising translational development possibilities.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Trott, O., & Olson, A. J. (2010) · Journal of Computational Chemistry · doi:10.1002/jcc.21334 · Cited by 38,412
The Phyre2 web portal for protein modeling, prediction and analysis
Kelley, L. A., Mezulis, S., Yates, C. M., Wass, M. N., & Sternberg, M. J. E. (2015) · Nature Protocols · doi:10.1038/nprot.2015.053 · Cited by 9,652 · cited 2×
“The tridimensional homology model of MAB_4508 was performed using the Phyre2 program (Kelley et al., 2015) using the crystal structure of Neisseria gonorrhoeae MtrD as template (Bolla et al., 2014), as reported earlier (Bernut et al., 2016).”
MethodDrugs for bad bugs: confronting the challenges of antibacterial discovery
Payne, D. J., Gwynn, M. N., Holmes, D. J., & Pompliano, D. L. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2201 · Cited by 2,512 · cited 1×
“…has been validated as an efficient method for the identification of novel structural classes of antimicrobials and proven to be more effective to generate lead compounds than VC 2016 John Wiley & Sons Ltd, Molecular Microbiology, 101, 515–529 rational drug-design strategies (Payne et al., 2007).”
MethodSLC24A5, a putative cation exchanger, affects pigmentation in zebrafish and humans
Lamason, R. L., Mohideen, M.-A. P. K., Mest, J. R., Wong, A. C., Norton, H. L., Aros, M. C., Jurynec, M. J., Mao, X., Humphreville, V. R., Humbert, J. E., et al. (2005) · Science · doi:10.1126/science.1116238 · Cited by 1,043 · cited 1×
“Experiments were performed using the golden mutant (Lamason et al., 2005).”
MethodInhibition of mycolic acid transport across the Mycobacterium tuberculosis plasma membrane
Grzegorzewicz, A. E., Pham, H., Gundi, V. A. K. B., Scherman, M. S., North, E. J., Hess, T., Jones, V., Gruppo, V., Born, S. E. M., Korduláková, J., et al. (2012) · Nature Chemical Biology · doi:10.1038/nchembio.794 · Cited by 442 · cited 6×
“Indeed, multiple chemotypes have recently been shown to inhibit MmpL3 which currently represents one of the most promising anti-tubercular drug targets (Grzegorzewicz et al., 2012; La Rosa et al., 2012; Tahlan et al., 2012; Lun et al., 2013; Remui~ n an et al., 2013; Cox et al., 2016).”
BackgroundMethodResultInfluentialMmpL Genes Are Associated with Mycolic Acid Metabolism in Mycobacteria and Corynebacteria
Varela, C., Rittmann, D., Singh, A., Krumbach, K., Bhatt, K., Eggeling, L., Besra, G. S., & Bhatt, A. (2012) · Chemistry & Biology · doi:10.1016/j.chembiol.2012.03.006 · Cited by 210 · cited 1×
“MmpL3 represents the only essential MmpL member in M. tuberculosis (Dome- nech et al., 2005) and in M. smegmatis (Varela et al., 2012) and has been shown to translocate trehalose- monomycolate (TMM) across the plasma membrane (Varela et al., 2012)(Grzegorzewicz et al., 2012).”
BackgroundLobo, L. J., Chang, L. C., Esther, C. R., Gilligan, P. H., Tulu, Z., & Noone, P. G. (2013) · Clinical Transplantation · doi:10.1111/ctr.12140 · Cited by 108 · cited 2×
“abscessus is considered as a contraindication for lung transplantation by several CF centres (Lobo et al., 2013), leaving patients without therapeutic options.”
Backgroundpks5-recombination-mediated surface remodelling in Mycobacterium tuberculosis emergence
Boritsch, E. C., Frigui, W., Cascioferro, A., Malaga, W., Etienne, G., Laval, F., Pawlik, A., Le Chevalier, F., Orgeur, M., Ma, L., et al. (2016) · Nature Microbiology · doi:10.1038/nmicrobiol.2015.19 · Cited by 104
Self-citation
Cited by
Non-tuberculous mycobacteria and the rise of Mycobacterium abscessus
Johansen, M. D., Herrmann, J.-L., & Kremer, L. (2020) · Nature Reviews Microbiology · doi:10.1038/s41579-020-0331-1 · Cited by 822
Self-citationNon-tuberculous mycobacterial pulmonary disease
Cowman, S., van Ingen, J., Griffith, D. E., & Loebinger, M. R. (2019) · European Respiratory Journal · doi:10.1183/13993003.00250-2019 · Cited by 302
NTM drug discovery: status, gaps and the way forward
Wu, M.-L., Aziz, D. B., Dartois, V., & Dick, T. (2018) · Drug Discovery Today · doi:10.1016/j.drudis.2018.04.001 · Cited by 276
Crystal Structures of Membrane Transporter MmpL3, an Anti-TB Drug Target
Zhang, B., Li, J., Yang, X., Wu, L., Zhang, J., Yang, Y., Zhao, Y., Zhang, L., Yang, X., Yang, X., et al. (2019) · Cell · doi:10.1016/j.cell.2019.01.003 · Cited by 263
Luthra, S., Rominski, A., & Sander, P. (2018) · Frontiers in Microbiology · doi:10.3389/fmicb.2018.02179 · Cited by 260
Metadata
- Authors
- Dupont, C., Viljoen, A., Dubar, F., Blaise, M., Bernut, A., Pawlik, A., Bouchier, C., Brosch, R., Guérardel, Y., Lelièvre, J., Ballell, L., Herrmann, J., Biot, C., & Kremer, L.
- Venue
- Molecular Microbiology
- Publisher
- Wiley
- Published
- 2016-06
- Volume
- 101
- Issue
- 3
- Pages
- 515-529
- ISSN
- 0950-382X (ISSN-L)
- 1365-2958
- OpenAlex
- W2342849480
- Cited by
- 119
- References
- 8
- FWCI
- 11.45
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.